BetterLife Pharma (BETRF), is an early-stage Canadian psychedelic drug development company. The companies lead drug candidate BETR-001 is being developed for headache disorders. BETR-001 is a fully non-hallucinogenic derivative of LSD. They expect to commence phase 1A and 1B clinical trials for cluster headache and migraine, in the first quarter of 2027, pending the public offering of US $100 million, scheduled by 9/15/2026. The company website is here Betterlifepharma.com.
Some important timelines from the past.
08/28/26: $100 million capital raise public offering, pending. Public Offering
05/13/26: Doug Drysdale as Executive Chairman and Director. Drysdale appointment
01/14/25: BETR-001 Composition of Matter Patent Granted 2042. BETR-001 Patent
11/15/23: US Patent Office publishes BETR-001. Published BETR-001
03/28/23: Published study of non-hallucinogenic LSD. Non-hallucinogenic LSD
09/27/21: Files patent for TD-0148A, 2-bromo-LSD (BETR-001). Patent Filed
12/20/20: All-stock transaction, acquired 100% of psychedelic biotech firm Transcend Biodynamics, gaining the rights to BOL-148, a proprietary LSD derivative, now referred to as BETR-001. Acquires Transcend Biodynamics
05/13/26: Doug Drysdale as Executive Chairman and Director. Drysdale appointment
01/14/25: BETR-001 Composition of Matter Patent Granted 2042. BETR-001 Patent
11/15/23: US Patent Office publishes BETR-001. Published BETR-001
03/28/23: Published study of non-hallucinogenic LSD. Non-hallucinogenic LSD
09/27/21: Files patent for TD-0148A, 2-bromo-LSD (BETR-001). Patent Filed
12/20/20: All-stock transaction, acquired 100% of psychedelic biotech firm Transcend Biodynamics, gaining the rights to BOL-148, a proprietary LSD derivative, now referred to as BETR-001. Acquires Transcend Biodynamics
In 2010, a study utilizing BOL-148 (non-hallucinogenic form of LSD) was initiated for cluster headache participants. This should be viewed as proof of concept study, with caveats. The general result of the study, was that all five participants had a response to the therapeutic. The link to that study is here. Cluster Headache Clinical Trial
Financial Statistics:
- 5M in cash
- 170 million diluted shares outstanding
- 37 million market cap
- 170 million diluted shares outstanding
- 37 million market cap
Intellectual Property:
- BETR-001 - Patent expected to expire into 2042
Timeline Catalyst:
- BETR-001: Begin a phase 1A, 1B clinical trial, first quarter of 2027
BetterLife Pharma (BETRF) is a clinical stage biotech company focused on the unmet medical need of cluster headaches and migraine. The stock is priced at $.23 cents per share (penny stock). There are risks to investing in this early stage drug development company, and return of capital invested is not a guarantee.
Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.
